

Identification of Microorganisms using Nucleic Acid Probes

Policy Number: AHS – M2097 – Identification of Microorganisms Using Nucleic Acid Probes	Prior Policy Name and Number, as applicable:
Policy Revision Date: 05/31/2023 Initial Policy Effective Date: 11/04/2021	

[POLICY DESCRIPTION](#) | [RELATED POLICIES](#) | [INDICATIONS AND/OR LIMITATIONS OF COVERAGE](#) | [TABLE OF TERMINOLOGY](#) | [SCIENTIFIC BACKGROUND](#) | [GUIDELINES AND RECOMMENDATIONS](#) | [APPLICABLE STATE AND FEDERAL REGULATIONS](#) | [APPLICABLE CPT/HCPCS PROCEDURE CODES](#) | [EVIDENCE-BASED SCIENTIFIC REFERENCES](#) | [REVISION HISTORY](#)

I. Policy Description

Nucleic acid hybridization technologies utilize complementary properties of the DNA double-helix structures to anneal together DNA fragments from different sources. These techniques are utilized in polymerase chain reaction (PCR) and fluorescent resonance energy transfer (FRET) techniques to identify microorganisms (Khan, 2014).

A discussion of every infectious agent that might be detected with a probe technique is beyond the scope of this policy. Many probes have been combined into panels of tests. For the purposes of this policy, only individual probes are reviewed.

For guidance on nucleic acid identification of *Candida* in vaginitis, please refer to AHS-M2057- Diagnosis of Vaginitis Including Multi-Target PCR Testing.

II. Related Policies

Policy Number	Policy Title
AHS-G2036	Hepatitis Testing
AHS-G2143	Lyme Disease
AHS-G2149	Pathogen Panel Testing
AHS-G2157	Diagnostic Testing of Common Sexually Transmitted Infections
AHS-G2158	Testing for Vector-Borne Infections
AHS-M2057	Diagnosis of Vaginitis Including Multi-Target PCR Testing

III. Indications and/or Limitations of Coverage

Application of coverage criteria is dependent upon an individual’s benefit coverage at the time of the request. Specifications pertaining to Medicare and Medicaid can be found in the “Applicable State and Federal Regulations” section of this policy document.

- 1) The coverage status of nucleic acid identification using direct probe, amplified probe, or quantification for the microorganism's procedure codes is summarized in Table 1 below. "MCC" in the table below indicates that the test **MEETS COVERAGE CRITERIA**; while "DNMCC" tests indicates that the test **DOES NOT MEET COVERAGE CRITERIA**.

Microorganism	Direct Probe	Amplified Probe	Quantification
<i>Bartonella henselae</i> or <i>quintana</i>		87471 (MCC)	87472 (DNMCC)
Non-vaginal <i>Candida</i> species	87480 (DNMCC)	87481 (DNMCC)	87482 (DNMCC)
<i>Chlamydia pneumoniae</i>	87485 (MCC)	87486 (MCC)	87487 (DNMCC)
<i>Clostridium difficile</i>		87493 (MCC)	
<i>Cytomegalovirus</i>	87495 (MCC)	87496 (MCC)	87497 (MCC)
<i>Enterococcus</i> , Vancomycin-resistant (e.g., enterococcus vanA, vanB)		87500 (MCC)	
<i>Enterovirus</i>		87498 (MCC)	
Hepatitis G	87525 (DNMCC)	87526 (DNMCC)	87527 (DNMCC)
Herpes virus-6	87531 (MCC)	87532 (DNMCC)	87533 (MCC)
<i>Legionella pneumophila</i>	87540 (MCC)	87541 (MCC)	87542 (DNMCC)
Orthopoxvirus		87593 (MCC)	
<i>Mycoplasma pneumoniae</i>	87580 (MCC)	87581 (MCC)	87582 (DNMCC)
<i>Mycoplasma genitalium</i>		87563 (MCC)	
Respiratory syncytial virus		87634 (MCC)	
<i>Staphylococcus aureus</i>		87640 (MCC)	
<i>Staphylococcus aureus</i> , methicillin resistant		87641 (MCC)	

- 2) Simultaneous ordering of any combination of direct probe, amplified probe, and/or quantification for the same organism in a single encounter **DOES NOT MEET COVERAGE CRITERIA**.

IV. Table of Terminology

Term	Definition
CDC	Centers for Disease Control and Prevention
CIDT	Culture-independent diagnostic test
CPT	Current procedural terminology
DFA	Direct fluorescent antibody testing
DNA	Deoxyribonucleic acid

Term	Definition
EVD	Ebola virus disease
FDA	Food and Drug Administration
FRET	Fluorescent resonance energy transfer
IDSA	Infectious Diseases Society of America
ITS	Internal transcribed region
Mpox	Monkeypox
MRSA	Methicillin-Resistant Staphylococcus Aureus
NAATs	Nucleic acid amplification tests
NGU	Nongonococcal urethritis
PCR	Polymerase chain reaction
PID	Pelvic inflammatory disease
qPCR	Quantitative polymerase chain reaction
rDNA	Recombinant deoxyribonucleic acid
RNA	Ribonucleic acid
rRT-PCR	Real-time reverse transcriptase-polymerase chain reaction
RSV	Respiratory syncytial virus infection
RT-PCR	Reverse transcriptase-polymerase chain reaction
SARS	Severe acute respiratory syndrome

V. Scientific Background

Nucleic acid hybridization technologies, including polymerase chain reaction (PCR), ligase- or helicase-dependent amplification, and transcription-mediated amplification, are beneficial tools for pathogen detection in blood culture and other clinical specimens due to high specificity and sensitivity (Khan, 2014). The use of nucleic acid-based methods to detect bacterial pathogens in a clinical laboratory setting offers “increased sensitivity and specificity over traditional microbiological techniques” due to its specificity, sensitivity, reduction in time, and high-throughput capability; however, “contamination potential, lack of standardization or validation for some assays, complex interpretation of results, and increased cost are possible limitations of these tests” (Mothershed & Whitney, 2006).

VI. Guidelines and Recommendations

World Health Organization (WHO)

For detection of monkeypox, the WHO recommends “detection of viral DNA by polymerase chain reaction (PCR)” as the preferred laboratory test and recommends that any individual with a suspected case should be offered testing. They note that the best specimens for diagnosis are taken directly from the rash. Antigen and antibody detection may not be able to distinguish between orthopoxviruses (WHO, 2022).

2018 Infectious Diseases Society of America (IDSA)

Specific guidelines for testing of many organisms listed within the policy coverage criteria is found in the updated 2018 Infectious Diseases Society of America (IDSA) guidelines and recommendations titled, “A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology” (Miller et al., 2018). “This document is organized by body system, although many organisms are capable of causing disease in >1 body system. There may be a redundant mention of some organisms because of their propensity to infect multiple sites. One of the unique features of this document is its ability to assist clinicians who have specific suspicions regarding possible etiologic agents causing a specific type of disease. When the term “clinician” is used throughout the document, it also includes other licensed, advanced practice providers. Another unique feature is that in most chapters, there are targeted recommendations and precautions regarding selecting and collecting specimens for analysis for a disease process. It is very easy to access critical information about a specific body site just by consulting the table of contents. Within each chapter, there is a table describing the specimen needs regarding a variety of etiologic agents that one may suspect as causing the illness. The test methods in the tables are listed in priority order according to the recommendations of the authors and reviewers” (Miller et al., 2018).

Centers of Disease Control and Prevention (CDC)

Candida Auris (C. auris)

The CDC writes that “Molecular methods based on sequencing the D1-D2 region of the 28S rDNA or the Internal Transcribed Region (ITS) of rDNA also can identify *C. auris*.” The CDC further notes that various PCR methods have been developed for identifying *C. auris* (CDC, 2020a).

Chlamydia Pneumoniae (C. pneumoniae)

The CDC writes that RT-PCR is the “preferred” method of detecting an acute *C. pneumoniae* infection. The CDC further notes that a positive culture should be confirmed by a second test, such as PCR (CDC, 2021a).

Ebola

The CDC states that for diagnosis of Ebola, “there must be a combination of symptoms suggestive of EVD **AND** a possible exposure to EVD within 21 days before the onset of symptoms.” Such exposures include

- blood or body fluids from a person sick with or who died from EVD,
- objects contaminated with blood or body fluids of a person sick with or who died from EVD,
- infected fruit bats and nonhuman primates (apes or monkeys), or
- semen from an individual who has recovered from EVD.

The CDC notes that PCR is one of the most common diagnostic methods, but also cautions that “When the virus is no longer present in great enough numbers in a patient’s blood, PCR methods will no longer be effective. Other methods, based on the detection of antibodies an EVD case

produces to an infection, can then be used to confirm a patient’s exposure and infection by Ebola virus” (CDC, 2022c).

Giardia

The CDC states that microscopy with direct fluorescent antibody testing (DFA) is considered the test of choice for diagnosing giardiasis, but rapid immunochromatographic cartridge assays, enzyme immunoassay kits, microscopy with trichrome staining, and molecular assays may be alternatively used as well. To obtain more accurate test results, the CDC recommends collecting three stool specimens from patients over the course of a few days. But, only molecular testing (e.g., DNA sequencing) can identify *Giardia* strains (CDC, 2021b).

Monkeypox Virus

The CDC defines a suspect case of monkeypox as a “new characteristic rash, or meets one of the epidemiologic criteria and has a high clinical suspicion for monkeypox.” A probable case is defined as “no suspicion of other recent Orthopoxvirus exposure (e.g., Vaccinia virus in ACAM2000 vaccination) AND demonstration of the presence of Orthopoxvirus DNA by polymerase chain reaction of a clinical specimen OR Orthopoxvirus using immunohistochemical or electron microscopy testing methods OR Demonstration of detectable levels of anti-orthopoxvirus IgM antibody during the period of 4 to 56 days after rash onset.” A confirmed case of monkeypox is defined as “demonstration of the presence of Monkeypox virus DNA by polymerase chain reaction testing or Next-Generation sequencing of a clinical specimen OR isolation of Monkeypox virus in culture from a clinical specimen” (CDC, 2022b).

MRSA

The CDC remarks that nucleic acid amplification tests (NAATs, such as PCR) “can be used for direct detection of *mecA*, the most common gene mediating oxacillin resistance in staphylococci,” but will not detect novel resistance mechanisms or uncommon phenotypes (CDC, 2019a).

Mycoplasma genitalium

For individuals with a penis who are experiencing recurrent nongonococcal urethritis (NGU), the CDC recommends FDA-cleared NAAT, with resistance testing done when available. The CDC also recommends that individuals with recurrent cervicitis should be tested for *M. genitalium*. Testing should be considered for individuals with pelvic inflammatory disease (PID). Testing should be accompanied with resistance testing, if available. The CDC does not recommend screening for *M. genitalium* for asymptomatic individuals, nor do they recommend extragenital testing for *M. genitalium*. “In clinical practice, if testing is unavailable, *M. genitalium* should be suspected in cases of persistent or recurrent urethritis or cervicitis and considered for PID” (CDC, 2021d).

Non-Polio Enterovirus

The CDC remarks that their laboratories “routinely” perform qualitative testing for enteroviruses, parechoviruses, and uncommon picornaviruses (CDC, 2018).

Respiratory Syncytial Virus (RSV)

The CDC writes that real-time reverse transcriptase-polymerase chain reaction (rRT-PCR) and antigen detection tests are the most commonly used diagnostic tests and are effective in infants and young children. However, the highly sensitive rRT-PCR is recommended to be used when testing older children and adults with RSV (CDC, 2022d).

Salmonella

The CDC writes that diagnosis requires detection of the *Salmonella* bacteria, be it through culture or a “culture-independent diagnostic test (CIDT)” (CDC, 2019b).

Miscellaneous

The CDC does not mention the need to quantify [through PCR] *Bartonella*, *Legionella pneumophila*, or *Mycoplasma pneumoniae*. However, PCR can be performed for both *Legionella pneumophila* and *Mycoplasma pneumoniae* specimen (CDC, 2020b, 2021c, 2022a). No guidance was found on Hepatitis G.

Committee on Infectious Diseases, American Academy of Pediatrics, 31st Edition (2018-2021, Red Book)

The Committee on Infectious Diseases released joint guidelines with the American Academy of Pediatrics. In it, they note that “the presumptive diagnosis of mucocutaneous candidiasis or thrush usually can be made clinically.” They also state that FISH probes may rapidly detect *Candida* species from positive blood culture samples, although PCR assays have also been developed for this purpose (AAP Committee on Infectious Diseases, 2018).

European Centre for Disease Prevention and Control (ECDC)

On May 23, 2022, the ECDC released a rapid risk assessment of the monkeypox multi-country outbreak. They recommend that patients with probable cases should be tested with a “monkeypox virus specific PCR or an orthopoxvirus specific PCR assay which is then confirmed through sequencing” (ECDC, 2022b).

On June 2, 2022, ECDC released interim advice on risk communication and community engagement during the 2022 monkeypox outbreak in Europe. This is a joint report with the WHO regional office for Europe. They recommend speaking to your doctor about getting tested for monkeypox if you develop a rash with a fever or feeling of discomfort or illness (ECDC, 2022a).

United Kingdom Health Security Agency (UKHSA)

The UKHSA states that “Mpx is diagnosed by PCR test for the monkeypox virus (MPXV) on a viral swab taken from one or more vesicles or ulcers.” Specifically, it is recommended that healthcare workers “Take a viral swab in viral culture medium or viral transport medium (for example Virocult®) from an open sore or from the surface of a vesicle. If other wounds are present, ensure that the sample is definitely taken from a vesicle, an ulcer or a crusted vesicle. Rub the swab over the lesion and place the swab in the collection tube. If there are pharyngeal

lesions, a throat swab should also be taken” (UKHSA, 2023). UKHSA also suggests that “A viral throat swab can be taken for high-risk contacts of a confirmed or highly probable case who have developed systemic symptoms but do not have a rash or lesions that can be sampled. Please note that even if the throat swab is negative, the individual must continue with monitoring and isolation as instructed by their local health protection team, and should be reassessed and sampled if further symptoms develop”. Lastly, “If follow-up testing is required from a confirmed or highly probable case, either because of clinical deterioration or to inform discharge from isolation to an inpatient setting, additional samples should be taken and should include the following:

- a lesion swab and throat swab in viral transport medium
- a blood sample in an EDTA tube
- a urine sample in a universal sterile container” (UKHSA, 2023).

VII. Applicable State and Federal Regulations

DISCLAIMER: If there is a conflict between this Policy and any relevant, applicable government policy for a particular member [e.g., Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) for Medicare and/or state coverage for Medicaid], then the government policy will be used to make the determination. For the most up-to-date Medicare policies and coverage, please visit the Medicare search website: <https://www.cms.gov/medicare-coverage-database/search.aspx>. For the most up-to-date Medicaid policies and coverage, visit the applicable state Medicaid website.

Food and Drug Administration (FDA)

Many labs have developed specific tests that they must validate and perform in house. These laboratory-developed tests (LDTs) are regulated by the Centers for Medicare and Medicaid (CMS) as high-complexity tests under the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88). LDTs are not approved or cleared by the U. S. Food and Drug Administration; however, FDA clearance or approval is not currently required for clinical use.

A list of current U.S. Food and Drug Administration (FDA, 2022) approved or cleared nucleic acid-based microbial tests is available at: <https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests>.

VIII. Applicable CPT/HCPCS Procedure Codes

CPT	Code Description
87471	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, amplified probe technique
87472	Infectious agent detection by nucleic acid (DNA or RNA); Bartonella henselae and Bartonella quintana, quantification
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
87481	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, amplified probe technique

CPT	Code Description
87482	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification
87485	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique
87486	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique
87487	Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, quantification
87493	Infectious agent detection by nucleic acid (DNA or RNA); Clostridium difficile, toxin gene(s), amplified probe technique
87495	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, direct probe technique
87496	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, amplified probe technique
87497	Infectious agent detection by nucleic acid (DNA or RNA); cytomegalovirus, quantification
87498	Infectious agent detection by nucleic acid (DNA or RNA); enterovirus, amplified probe technique, includes reverse transcription when performed
87500	Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique
87525	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, direct probe technique
87526	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, amplified probe technique
87527	Infectious agent detection by nucleic acid (DNA or RNA); hepatitis G, quantification
87531	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, direct probe technique
87532	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, amplified probe technique
87533	Infectious agent detection by nucleic acid (DNA or RNA); Herpes virus-6, quantification
87540	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, direct probe technique
87541	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, amplified probe technique
87542	Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification
87563	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma genitalium, amplified probe technique
87580	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, direct probe technique

CPT	Code Description
87581	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique
87582	Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, quantification
87593	Infectious agent detection by nucleic acid (DNA or RNA); orthopoxvirus (eg, monkeypox virus, cowpox virus, vaccinia virus), amplified probe technique, each
87634	Infectious agent detection by nucleic acid (DNA or RNA); respiratory syncytial virus, amplified probe technique
87640	Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique
87641	Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique

Current Procedural Terminology© American Medical Association. All Rights reserved.

Procedure codes appearing in Medical Policy documents are included only as a general reference tool for each policy. They may not be all-inclusive.

IX. Evidence-based Scientific References

- AAP Committee on Infectious Diseases. (2018). *Red Book® 2018*.
- CDC. (2018, November 14). Non-Polio Enterovirus, CDC Laboratory Testing & Procedures. Retrieved from <https://www.cdc.gov/non-polio-enterovirus/lab-testing/testing-procedures.html>
- CDC. (2019a, February 6). Methicillin-resistant Staphylococcus aureus (MRSA), Laboratory Testing. Retrieved from https://www.cdc.gov/mrsa/lab/index.html#anchor_1548439781
- CDC. (2019b, December 5). Salmonella, Diagnostic and Public Health Testing. Retrieved from <https://www.cdc.gov/salmonella/general/diagnosis-treatment.html>
- CDC. (2020a, May 29). Identification of Candida auris. Retrieved from <https://www.cdc.gov/fungal/candida-auris/identification.html>
- CDC. (2020b, June 5). Mycoplasma pneumoniae Infections - Diagnostic methods Retrieved from <https://www.cdc.gov/pneumonia/atypical/mycoplasma/hcp/diagnostic-methods.html>
- CDC. (2021a, November 15). Chlamydia pneumoniae Infection, Diagnostic Methods. Retrieved from <https://www.cdc.gov/pneumonia/atypical/cpneumoniae/hcp/diagnostic.html>
- CDC. (2021b, March 1). Diagnosis and Treatment Information for Medical Professionals. Retrieved from <https://www.cdc.gov/parasites/giardia/medical-professionals.html>
- CDC. (2021c, March 25). Legionella (Legionnaires' Disease and Pontiac Fever) - Diagnosis, Treatment, and Prevention. Retrieved from <https://www.cdc.gov/legionella/clinicians/diagnostic-testing.html>
- CDC. (2021d, July 22). Sexually Transmitted Infections Treatment Guidelines, 2021. Retrieved from <https://www.cdc.gov/std/treatment-guidelines/mycoplasmagenitalium.htm>
- CDC. (2022a, January 10). Bartonella Infection. Retrieved from <https://www.cdc.gov/bartonella/bartonella-henselae/index.html>
- CDC. (2022b, July 22). Case Definitions† for Use in the 2022 Monkeypox Response. Retrieved from <https://www.cdc.gov/poxvirus/monkeypox/clinicians/case-definition.html>

CDC. (2022c, December 8). Ebola (Ebola Virus Disease), Diagnosis. Retrieved from <https://www.cdc.gov/vhf/ebola/diagnosis/index.html>

CDC. (2022d, October 28). Respiratory Syncytial Virus Infection (RSV), For Healthcare Professionals. Retrieved from <https://www.cdc.gov/rsv/clinical/index.html#lab>

ECDC. (2022a). *Interim advice on Risk Communication and Community Engagement during the monkeypox outbreak in Europe, 2022*. Retrieved from <https://www.ecdc.europa.eu/sites/default/files/documents/Joint-ECDC-WHO-interim-advice-on-RCCE-for-Monkeypox-2-June-2022.pdf>

ECDC. (2022b). *Risk assessment: Monkeypox multi-country outbreak*. Retrieved from <https://www.ecdc.europa.eu/en/publications-data/risk-assessment-monkeypox-multi-country-outbreak>

FDA. (2022, April 19). Nucleic Acid Based Tests. Retrieved from <https://www.fda.gov/medical-devices/vitro-diagnostics/nucleic-acid-based-tests>

Khan, A. (2014). Rapid Advances in Nucleic Acid Technologies for Detection and Diagnostics of Pathogens. *J Microbiol Exp*, 1(2). doi:10.15406/jmen.2014.01.00009

Miller, J. M., Binnicker, M. J., Campbell, S., Carroll, K. C., Chapin, K. C., Gilligan, P. H., . . . Yao, J. D. (2018). A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. *Clinical Infectious Diseases*, ciy381-ciy381. doi:10.1093/cid/ciy381

Mothershed, E. A., & Whitney, A. M. (2006). Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory. *Clin Chim Acta*, 363(1-2), 206-220. doi:10.1016/j.cccn.2005.05.050

UKHSA. (2023, February 15). Monkeypox: diagnostic testing. Retrieved from <https://www.gov.uk/guidance/monkeypox-diagnostic-testing>

WHO. (2022). Monkeypox. Retrieved from https://www.who.int/health-topics/monkeypox/#tab=tab_1

X. Review/Revision History

Effective Date	Summary
10/15/2023	<p>Reviewed and Updated: Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>In the table within CC1, references to Candida testing for vaginitis were removed, row now specifies “non-vaginal Candida”. Directive to see M2057 for vaginal Candida moved into policy description.</p> <p>87493 for C. diff moved from “Direct Probe” column to “Amplified Probe” column.</p> <p>Heptatis B removed from the table in CC1 due to the expansion of G2036 to include Hepatitis B testing.</p> <p>Removed former CC3: “3) For any other microorganism without a specific CPT code, PCR testing MEETS COVERAGE CRITERIA.”</p> <p>Former “Policy Guideline” was moved into the Policy Description.</p>

	Removed CPT codes 87516, 87517, 87797, 87798, and 87799.
05/01/2023	<p>Updated background, guidelines, and evidence-based scientific references. Literature review necessitated the following changes in coverage criteria:</p> <p>Addition of “Orthopoxvirus” to the table in CC1. Code 87593 added in the “Amplified Probe” column in its row as “MCC” to allow for coverage of the amplified probe test for orthopoxvirus (monkeypox is an orthopoxvirus)</p> <p>CC2 edited for clarity, now reads: “Simultaneous ordering of any combination of direct probe, amplified probe, and/or quantification for the same organism in a single encounter DOES NOT MEET COVERAGE CRITERIA.”</p> <p>CC3 edited to remove specific list of organisms, as it was not all inclusive. Now reads: “For any other microorganism without a specific CPT code, PCR testing MEETS COVERAGE CRITERIA.”</p> <p>Removed “*DNMCC= Does Not Meet Coverage Criteria; MCC = Meets coverage criteria.” from beneath the table in CC1, as the definition was redundant with what was already provided in CC1.</p> <p>Added CPT code 87593 (new orthopoxvirus CPT code effective 7/26/2022)</p>
11/04/2021	Initial Policy Implementation